ABSTRACT
BACTERIA Pseudomonas Aeruginosa With the advent of routine prophylactic antimicrobial therapy, infections caused by P. aeruginosa have been declining since the 1970s in patients with cancer [1,2]. Currently, P. aeruginosa accounts for 5 to 10% of all bacteremia in patients with neutropenia [2]. Colonization can lead to pneumonia, typhlitis (neutropenic enterocolitis), and perineal cellulitis. Other sites of infection include the urinary tract, the skin and soft tissue, and central venous catheters [2]. Immunocompromised patients, especially neutropenics, are at greatest risk of pseudomonal infection.
